Evrysdi is the only FDA-approved, noninvasive, disease-modifying treatment for spinal muscular atrophy. The tablets offer similar safety and efficacy as the original oral solution. The FDA has ...

For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...

The Food and Drug Administration approved Vertex Pharmaceuticals’ “Journavx” on Thursday, greenlighting the non-opioid painkiller for treating moderate to severe pain in what the FDA ...

It’s the first of a new class of analgesics to be approved in over 20 years, and, importantly, it isn’t addictive. On the 30th of January 2025, the FDA approved 50-mg tablets of the novel ...

Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images.

Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be approved by the FDA for complicated intra-abdominal infections with limited ...

For the first time in two decades, the FDA has approved a new class of non-opioid pain medication, offering an alternative to addictive opioids for patients seeking pain relief. The drug ...

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. “Today’s approval ...

Ozempic is already widely used and was first FDA-approved in 2017 to treat type 2 diabetes. The medication — taken weekly by injection in the thigh, stomach or arm — is a brand name for ...

The approval was based on results from a split-face trial comparing the two products with Restylane-L. Perspective from Macrene Alexiades, MD, PhD The FDA has approved Evolysse Form and Evolysse ...

Jan. 31, 2025 – The FDA has approved a new non-opioid oral drug for acute pain in adults. It is the first new class of non-opioid pain medicine approved in over 20 years, providing effective ...